Remove 2011 Remove Patients Remove Side effects
article thumbnail

“Game-changing” obesity drug over-promising?

World of DTC Marketing

Patients want quick fixes, and the idea of losing some weight because of a new drug is enticing to them. In response, the company has been providing six-month waivers to some insured patients that will cap the drug’s out-of-pocket costs at $25 a month, though the long-term picture of coverage is still in flux. Click to Tweet.

Insurance 271
article thumbnail

Thursday pharma headlines

World of DTC Marketing

regulators knew about reports of suicidal behavior in men taking the anti-baldness treatment Propecia when they decided not to warn consumers of those potential risks in a 2011 update of the popular drug’s label. Newly unsealed court documents show that Merck and U.S. Annual U.S. He said it would take years to analyze all the data.

Pharma 180
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

In September, a group from Friedrich Alexander University Erlangen-Nuremberg reported that five patients with lupus achieved remission after an infusion of autologous chimeric antigen receptor (CAR)-T cells led to a deep depletion of B cells. All five patients achieved remission after three months.

article thumbnail

Innovating allergy drug delivery with a needle-free alternative

European Pharmaceutical Review

Additionally, EURneffy could alleviate the risk of accidental needle-related side effects (such as injection into the blood vessel and hand) 3 and it has the attributes of being smaller in size, has better temperature sensitivity, and is less complex to use compared to needle-based injectors. Hand (N Y). 2007; 2(1):5-11.

article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4 As of October 2023, 62.93

Medicine 116
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

article thumbnail

Healthcare stories in the news

World of DTC Marketing

“New weight loss drugs help patients lose significant weight,” but very few are telling the whole story. They can be expensive and have serious side effects. Those capital investment companies’ demand for return on investment and the debt load they force hospices to bear are hurting patients and their families.